Will an upcoming Senate hearing help lower drug prices? It depends who you ask
Days before three pharma CEOs are set to testify before the Senate on high prescription drug prices, members of the Committee on Health, Education, Labor, and Pensions (HELP) are debating whether another such hearing will have a major impact on the debate.
Sen. Bernie Sanders (I-VT) released a new report on Tuesday criticizing “corporate greed” in the pharmaceutical industry, attacking high launch prices, drugmakers’ lobbying efforts and “exorbitant compensation packages” for chief executives. In the majority staff report, HELP members said Keytruda’s 2022 sales alone came $2 billion shy of McDonald’s global revenue that year and surpassed sales from the hotel chain Marriott.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.